Received: 20 March 2020
Accepted: 3 November 2020
First Online: 4 January 2021
: G.M.D. declares competing financial interests and has submitted patents covering the use of PGC-1α in cell therapies that are licensed or pending and is entitled to a share in net income generated from licensing of these patent rights for commercial development. He consults for and/or is on the scientific advisory board of BlueSphere Bio, Century Therapeutics, Novasenta, Pieris Pharmaceuticals and Western Oncolytics/Kalivir; has grants from bluebird bio, Novasenta, Pfizer, Pieris Pharmaceuticals, TCR2 and Western Oncolytics/Kalivir; and owns stock in Novasenta.
Free to read: This content has been made available to all.